Recent
View AllGilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing…
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with…
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like…
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse…
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading…
Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In…
The Dow Jones Industrial Average ($INDU) may not be the comprehensive measure of the US economy it once was…
While the S&P 500 continues to move higher, the number of stocks participating to the upside continues to decline.…